Jim Haley is the former co-head of patents in the IP corporate group of Ropes & Gray. His practice focuses on the worldwide procurement and enforcement of patents in the biotechnology, biopharmaceutical and pharmaceutical industries. He has counselled biopharmaceutical clients since 1978 and drafted, prosecuted and defended some of the basic patents in biotechnology. Those patents have garnered over US$4 billion in royalties.
Some of Mr Haley’s representative infringement cases include Shelbyzyme v Genzyme (D Del), Genzyme v Anika Therapeutics (D Mass), Genzyme v Zimmer (D Mass), Pieczenik v Abbott (D NJ), MEEI v QLT/Novartis Ophthalmics (D Mass), MEEI v QLT (D Mass), Amgen v Aventis/TKT (D Mass), Oregon Health & Sciences University v Vertex Pharmaceuticals, Inc (D Oregon), Biogen v Berlex (D Mass), Pieczenik v Dyax (D Mass/SDNY), Biogen v Amgen (D Mass), Biogen v Thomae (Germany), Biogen v Bender (Austria), Biogen v BTG (Israel), Biogen v Medeva (United Kingdom), Yamanouchi v Biogen (France, Italy, the Netherlands and Germany), Biogen v Scitech (Singapore), Biogen v Amgen (Japan), Biogen v Sumitomo (Japan), Biogen v Pharmacia (Sweden), Biogen v Pharmacia (United States), Schering-Plough v Sterling Winthrop (United States), Boehringer Ingelheim v Bioferon (Germany), Sheller Globe v Milsco (United States), Square D v 3M (United States), PPG v Celanese (United States), Case v BASF (United States), Amgen v TKT/Aventis (United Kingdom), and Biogen v BTG (Israel).
Some of Mr Haley’s representative oppositions include the European Patent Office (IL-1 Inhibitor, phage display, expression vectors, alpha interferon, hepatitis B viral antigens, gamma interferon, beta interferon, xenomice and antibodies, protein secretion, imaging agents and B-cell activating factor, bone growth and cartilage repair), Germany (beta interferon), Australia (gamma interferon and antiviral compounds), and Japan (beta interferon, protein secretion, alpha interferon and antiviral nucleosides).
Some of Mr Haley’s representative interferences include Il-13 binding chain, M-CSF antibodies, B-cell activating factor, TWEAK, alpha interferon, hepatitis B viral antigens, protein secretion, leukocyte adhesion molecules, beta interferon, interleukin 1 converting enzyme inhibitors and bone morphogenic proteins, CD40 counterreceptor antibodies and transgenic fibrinogen.